Roy H. Pottier

TL;DR: In the ongoing clinical trial of ALA-induced Pp IX photodynamic therapy, the response rate for basal cell carcinomas following a single treatment has been 90% complete response and 7.5% partial response for the first 80 lesions treated.

TL;DR: Preclinical studies in experimental animals and human volunteers indicate that ALA can induce a localized tissue-specific photosensitization if administered by intradermal injection, opening the possibility of using ALA-induced PpIX to treat tumors that are too thick or that lie too deep to be accessible to either topical or locally injected ALA.

TL;DR: Fluorescence emission and fluorescence excitation spectroscopy led to the conclusion that the chromophore(s) responsible for this naturally occurring fluorescence is/are pheophorbide a and/or pheophytin a, degradation products of chlorophyll a that are derived from the mouse food.

TL;DR: In this article, drugs for detecting and treating malignant and nonmalignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids containing suspended abnormal cells, and for treating cancers of the nervous system are prepared from 5-aminolevulinic acid or precursor thereof and subsequently administered to the patient in an amount sufficient to induce syntheses fluorescence and/or photosensitizing concentrations or protoporphyrin IX